Hangzhou Biotest Biotech Co.,Ltd.

XSSC:688767 Stock Report

Market Cap: CN¥3.2b

Hangzhou Biotest BiotechLtd Valuation

Is 688767 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 688767 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 688767 (CN¥30.92) is trading above our estimate of fair value (CN¥3.23)

Significantly Below Fair Value: 688767 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 688767?

Key metric: As 688767 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 688767. This is calculated by dividing 688767's market cap by their current earnings.
What is 688767's PE Ratio?
PE Ratio31x
EarningsCN¥104.29m
Market CapCN¥3.23b

Price to Earnings Ratio vs Peers

How does 688767's PE Ratio compare to its peers?

The above table shows the PE ratio for 688767 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average107.1x
300381 Guangdong VTR Bio-Tech
185.8xn/aCN¥3.7b
300238 Guanhao BiotechLtd
201.8xn/aCN¥3.5b
300439 Medicalsystem Biotechnology
17.5xn/aCN¥4.4b
300653 Yantai Zhenghai Biotechnology
23.3x15.0%CN¥3.8b
688767 Hangzhou Biotest BiotechLtd
31xn/aCN¥3.2b

Price-To-Earnings vs Peers: 688767 is good value based on its Price-To-Earnings Ratio (31x) compared to the peer average (107.3x).

Price to Earnings Ratio vs Industry

How does 688767's PE Ratio compare vs other companies in the CN Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
688767 31.0xIndustry Avg. 35.5xNo. of Companies6PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 688767 is good value based on its Price-To-Earnings Ratio (31x) compared to the CN Biotechs industry average (36x).

Price to Earnings Ratio vs Fair Ratio

What is 688767's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

688767 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio31x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 688767's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sichuan Kelun Pharmaceutical

CN¥49.3b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥32.66

7D

2.6%

1Y

14.2%

Dong-E-E-JiaoLtd

CN¥36.7b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥58.18

7D

-0.4%

1Y

15.5%

China Resources Double-Crane PharmaceuticalLtd

CN¥21.2b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥21.11

7D

-5.1%

1Y

14.5%